Wilson Disease (Hepatolenticular Degeneration)
An inherited disorder of copper metabolism that causes toxic copper buildup in the liver, brain, and eyes, which is treatable when identified and managed early.
- Treatable when diagnosed early
- Lifelong chelation or zinc therapy
- Specialist hepatology and neurology care
- Inheritance Pattern
- Autosomal Recessive
- Gene Involved
- ATP7B
- Typical Onset
- Childhood to Young Adulthood
- Key Therapy
- Chelation Agents, Zinc, Liver Transplant
Condition Overview
Wilson disease is an inherited disorder of copper metabolism caused by mutations in the ATP7B gene, which normally helps transport excess copper out of liver cells and into bile for excretion. When ATP7B function is impaired, copper accumulates first in the liver and later spills over into the bloodstream, depositing in the brain, eyes, and other tissues.
Because copper is toxic to cells in excess, this accumulation can cause a wide range of problems, most commonly liver disease and neuropsychiatric symptoms such as tremor, difficulty with coordination, and mood or behavioral changes. Symptoms most often appear between childhood and young adulthood, though presentation can occur at almost any age.
Wilson disease is one of the few genetic disorders that is highly treatable when recognized early, since copper-removing medications and dietary changes can prevent or reverse much of the organ damage if started before advanced disease develops.
Types and Subtypes
Wilson disease is usually categorized by the dominant organ system involved at presentation, which influences the initial diagnostic and treatment approach.
Symptoms and Signs
Symptoms reflect copper accumulation in the liver, brain, and eyes, and can develop gradually or, less commonly, present acutely.
Causes and Risk Factors
Wilson disease is caused entirely by inherited changes in the ATP7B gene; it is not caused by diet or lifestyle, although copper intake can influence symptom severity once disease is present.
Diagnosis and Investigations
Diagnosis combines blood and urine copper studies, eye examination, and increasingly genetic testing.
Disease Severity and Risk Stratification
Wilson disease is not staged like a cancer; severity is generally classified by organ involvement and the presence of acute decompensation.
Standard Treatment Options
Treatment focuses on removing excess copper and then preventing reaccumulation, usually for life.
Advanced and Emerging Therapies
While chelation and zinc remain the backbone of treatment, newer agents and approaches are under active investigation.
Targeted Copper-Binding Agent
Bis-choline Tetrathiomolybdate
An investigational agent designed to directly bind copper and reduce free copper levels, studied as a potential alternative to traditional chelators, particularly for neurologic disease.
Liver-Directed Therapy
Liver Transplantation
Curative for the metabolic defect in appropriately selected patients with decompensated liver disease.
Research Direction
Gene Therapy Approaches
Early preclinical and early-phase research is exploring ATP7B gene replacement strategies, though these remain investigational and are not yet broadly available.
Biomarkers and Precision Medicine
Several laboratory markers guide diagnosis, treatment monitoring, and risk assessment in Wilson disease.
When a Second Opinion May Be Important
Because Wilson disease can mimic other liver or neurologic conditions, specialist input is valuable at several key decision points.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Wilson disease has a generally favorable prognosis when diagnosed and treated early, with many patients living full lives on long-term therapy. Outcomes are less favorable when diagnosis is delayed until advanced liver or neurologic disease has developed.
Supportive Care and Living with Wilson Disease
Living with Wilson disease involves lifelong medication adherence, dietary awareness, and monitoring, alongside support for any neurologic or psychiatric symptoms.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with Wilson disease get specialist medical report review, coordinate second opinions with hepatology and neurology experts, and access information on liver transplant evaluation and emerging copper-binding therapies.
Get a free case reviewFrequently Asked Questions
Wilson disease is an inherited disorder caused by mutations in the ATP7B gene that lead to toxic copper buildup in the liver, brain, and eyes.
Early signs often include unexplained liver enzyme abnormalities, fatigue, or in some patients tremor, clumsiness, or mood changes.
It is not curable in the sense of removing the genetic cause, but it is highly treatable; lifelong copper-removing therapy can prevent or reverse much organ damage, especially when started early.
Diagnosis typically combines ceruloplasmin levels, 24-hour urinary copper testing, eye examination for Kayser-Fleischer rings, and genetic testing of ATP7B.
It is a golden-brown copper deposit visible at the edge of the cornea on slit-lamp examination, common in patients with neurologic involvement.
Chelating agents such as penicillamine and trientine remove excess copper, while zinc salts are often used for long-term maintenance therapy.
Yes, it follows an autosomal recessive pattern, meaning a person must inherit an altered ATP7B gene copy from each parent.
Yes, siblings are typically recommended for screening, since early identification before symptoms develop leads to better outcomes.
Transplant is generally reserved for acute liver failure or advanced decompensated cirrhosis that does not respond to medical therapy.
Yes. CancerFax can help patients obtain medical report review, coordinate second opinions with hepatology and neurology specialists, and explore options including transplant evaluation and emerging therapies.